# PNC-27

> PNC-27 is an experimental peptide derived from a fragment of the p53 tumor suppressor protein that is designed to bind HDM-2 (also called MDM2), a protein overexpressed on the cell membrane of many cancer cell types. It has been studied exclusively in laboratory settings, including in vitro cancer cell cultures and limited animal models, with the proposed goal of selectively killing cancer cells while sparing normal cells. No completed human clinical trials, FDA approval, or established human dosing exist for PNC-27, and it is not an approved or prescribed medication. Any human use occurs outside formal clinical research and regulatory oversight, and its safety and efficacy in humans are unverified.

- URL: https://www.lifeconverted.com/peptides/pnc-27
- Primary category: Other & Clinical
- Effectiveness rank: #28 in Other & Clinical
- Evidence level: Emerging research
- Route: Subcutaneous (No human clinical routes of administration have been established or approved; subcutaneous use reflects informal research-chemical practice, not a validated protocol.)
- Dose range: 250-1,000 mcg
- Dose tiers: low 250 mcg; moderate 500 mcg; high 1000 mcg
- Half-life: Not established in humans; likely short (on the order of minutes) based on its peptide size and structure, but this is unconfirmed
- Timing: As directed by your clinician
- Cycle: No established clinical protocol exists; informally reported use patterns describe courses lasting several weeks on, No established or validated washout period exists off (PNC-27 has not completed human clinical trials; all available efficacy and safety data come from in vitro and limited animal studies. It is not an approved drug.)
- Storage: If obtained as a research peptide, typically reconstituted and refrigerated at 2-8°C, protected from light, and used promptly, consistent with general peptide handling practices; this reflects general peptide storage convention rather than a validated protocol specific to this compound.

## Mechanism of action

PNC-27 is designed to bind HDM-2 protein expressed on the outer membrane of cancer cells, a feature reportedly much less common on normal, non-cancerous cells. In laboratory studies, this binding has been proposed to trigger pore formation in the cancer cell membrane, leading to cell lysis and necrosis rather than the slower, more targeted process of apoptosis. Because this proposed mechanism relies on preferential HDM-2 membrane expression in cancer cells, its selectivity and effects have not been confirmed in human clinical studies.

## Reported benefits

- Proposed selective cytotoxic activity against cancer cells in preclinical laboratory studies
- Investigated mechanism distinct from conventional chemotherapy, potentially relevant to future research
- Represents an active area of academic cancer-biology research

## Reported side effects

- No human safety data exist; potential risks in humans are unknown
- Effects observed only in vitro and in limited animal models may not translate to humans
- Unregulated research-chemical sourcing carries risks of impurity, mislabeling, or contamination
- Theoretical risk of unpredictable immune or tissue reactions given the lack of human testing

## Common protocols

- No established clinical protocol; used exclusively in laboratory in vitro and animal cancer-cell studies to date

## Stacking notes

No human safety or drug-interaction data exist; combining with other experimental compounds is unstudied and is discouraged outside formal, regulated research settings.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer